European NGOs alert pharmaceutical pressure on the reform of medicines in the European Union
propagandaThree large NGOs indicated this week You are concerned that great medications are trying to influence In reforms The pharmaceutical framework of the European Union Convincing the European Commission to enter new incentives to support innovation in the midst of the growing global trade tensions.
The European Cancer Association (ECL), the European Consumer Organization (BeUC) and the Mutual International Association (AIM) also warned in a joint statement addressed to the CEO of Society Increased costs of innovative medicines Keep out of the reach of many patients, which exacerbates healthy inequality throughout Europe.
Organizations also requested governments Giving priority to patients and consumers Ensure affordable prices to safe and effective medications. Since the committee has presented A proposal to repair medicines in May 2023Discussions in the European Parliament advanced, but they barely advanced in the European Union Council.
The European Union CEO said it was still Optimistic about the possibility of achieving a positive result Through the ongoing negotiations with legislators. It is expected that representatives of the European Union member states will meet again next week to continue negotiations on the package.
According to the minutes of the meeting obtained by “Euronws”, European Union diplomats approached last Monday Supply safetyParallel trade and innovation, but it did not feed on the thorny issue of organizational protection. After a meeting with the chairman of the committee, Ursula von der Lin, the executives in the pharmaceutical industry, reiterated their request to enhance intellectual property protection.
Great savings for European health systems
The periods of protecting the regulatory data prevent competitors from using the data provided by companies to Proof that new drugs are safe and effectiveWhich helps them to produce its equivalent cheaper or biological.
For their part, civil society groups invite Decrease in the basic data protection period Organization – currently appointed in eight years – to allow a previous sexual and biological entry into the market. They argue that this change can save European health systems About 1130 million euros annually.
“Cancer treatment is Impossible without access to medications And care for reasonable prices. The main goal of the European Union pharmaceutical reform should continue to be clear: to ensure that all cancer patients can reach medications that save medications when they need more, “said Toma Mikalaskite, responsible for ECL policies.
However, pharmaceutical companies They click to achieve more appropriate conditions. Your demands are not only because of interest b A possible pharmaceutical trade war with the United StatesBut also for changes in US national policy.
Will there be an increase in prices in Europe?
Pharmaceutical companies are more afraid and more than if the prices of medicines in the European Union are still low, and this It can affect drug prices policies In the United States, especially amid the discussions that started under the Trump administration to compare the prices of American drugs with the prices of other developed countries.
Companies are concerned about this Low European prices can exert pressure On the prices of the United States, which would lead them to pressure this Prices increase in Europe.
Large companies such as French Sanofi and Switzerland also pressed a joint speech, on the pretext Strict price controls in Europe They cause the European Union market to be less attractive compared to the United States, as it is allowed to rise in drug prices.
